Top

Osteoporosis International

Published in:

01-01-2013 | Original Article

Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study

Authors: J.-H. Kang, J. J. Keller, H.-C. Lin

Published in: Osteoporosis International | Issue 1/2013

Abstract

Summary

This population-based matched cohort analysis explored the effects of bisphosphonate treatment on acute myocardial infarction (AMI). We found that patients who received bisphosphonate therapy had a lower risk of AMI during a 2-year follow-up period (hazard ratio (HR) = 0.35). Our data support that bisphosphonates may provide protective effects against cardiovascular events.

Introduction

Although bisphosphonates have been suggested to have anti-atherosclerotic effects in animal models, evidence in human subjects is still conflicting. Therefore, this study aimed to explore the effects of bisphosphonate treatment on AMI using a population-based cohort study.

Methods

We identified 1,548 patients who received bisphosphonate therapy for osteoporotic fractures and randomly extracted 4,644 subjects with vertebral or hip fractures as a comparison cohort. Each patient was individually tracked for 2 years to identify those who subsequently suffered an AMI. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of AMI.

Results

Six (0.4 %) of the patients who received bisphosphonate therapy and 49 (1.1 %) of the comparison subjects suffered an AMI during the 2-year follow-up period. The incidence rate of AMI was 1.94 (95 % CI = 0.79–4.03) per 1,000 person-years in patients who received bisphosphonate therapy and 5.28 (95 % CI = 3.95–6.92) per 1,000 person-years in comparison patients. Regression analysis revealed that patients who received bisphosphonate therapy had a lower hazard of AMI during the 2-year follow-up period than comparison patients (HR = 0.37, 95 % CI = 0.16–0.85, p = 0.020). After censoring cases that died from non-AMI causes and adjusting for both demographic and risk factors, the HR of AMI for patients who received bisphosphonate therapy was 0.35 (95 % CI = 0.14–0.84, p = 0.020) than that of comparison patients.

Conclusions

Patients who received bisphosphonate therapy had a lower risk of AMI during the 2-year follow-up period. Our data support that bisphosphonates may provide protective effects against cardiovascular events.

Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRef

Rodan GA, Reszka AA (2002) Bisphosphonate mechanism of action. Curr Mol Med 2:571–577PubMedCrossRef

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRef

Cummings SR, Karpf DB, Harris F et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289PubMedCrossRef

Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327:89–95PubMedCrossRef

Lyles K, Colón-Emeric C, Magaziner J, for the HORIZON Recurrent Fracture Trial et al (2007) Zoledronic acid and clinical fracture and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef

Beaupre LA, Morrish DW, Hanley DA et al (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991PubMedCrossRef

Sambrook PN, Cameron ID, Chen JS et al (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551–2556PubMedCrossRef

Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014PubMedCrossRef

10.

Martin CK, Werbeck JL, Thudi NK et al (2010) Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma. Cancer Res 70:8607–8616PubMedCrossRef

11.

Colon-Emeric CS, Mesenbrink P, Lyles KW et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMedCrossRef

12.

Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207PubMedCrossRef

13.

Baldini V, Mastropasqua M, Francucci CM, D'Erasmo E (2005) Cardiovascular disease and osteoporosis. J Endocrinol Investig 28:69–72

14.

den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF (2011) (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther 13:R5

15.

Doherty TM, Fitzpatrick LA, Inoue D et al (2004) Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 25:629–672PubMedCrossRef

16.

Mussolino ME, Gillum RF, Madans JH (2001) Bone mineral density and stroke risk. Stroke 32:2956–2957PubMed

17.

Mussolino ME, Madans JH, Gillum RF (2003) Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study. Ann Epidemiol 13:692–697PubMedCrossRef

18.

Tanko LB, Bagger YZ, Christiansen C (2003) Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73:15–20PubMedCrossRef

19.

Hyder JA, Allison MA, Barrett-Connor E et al (2010) Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. Atherosclerosis 209:283–289PubMedCrossRef

20.

Jorgensen L, Joakimsen O, Rosvold Berntsen GK, Heuch I, Jacobsen BK (2004) Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. Am J Epidemiol 160:549–556PubMedCrossRef

21.

Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V (2004) Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246–4253PubMedCrossRef

22.

Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O’Donnell CJ, Wilson PW (2001) Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 68:271–276PubMedCrossRef

23.

Hyder JA, Allison MA, Wong N et al (2009) Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol 169:186–194PubMedCrossRef

24.

Jensky NE, Hyder JA, Allison MA et al (2011) The association of bone density and calcified atherosclerosis is stronger in women without dyslipidemia: the multi-ethnic study of atherosclerosis. J Bone Miner Res 26:2702–2709PubMedCrossRef

25.

Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA (2009) Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 5:185–197PubMedCrossRef

26.

Fiore CE, Pennisi P, Pulvirenti I, Francucci CM (2009) Bisphosphonates and atherosclerosis. J Endocrinol Investig 32:38–43

27.

Strandberg TE (2008) Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med 168:2386–2387, author reply 7PubMedCrossRef

28.

Watts N (2002) Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J 95:578–582PubMed

29.

Kang JH, Keller JJ, Lin HC (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23(10):2551–2557PubMedCrossRef

30.

Coats AJS, Shewan LG (2011) Statement on authorship and publishing ethics in the International Journal of Cardiology. Int J Cardiol 153:239–240PubMed

31.

Chung KH, Lee HC, Kao S, Lin HC (2008) Urbanicity and methods of suicide: a nationwide population-based study. J Urban Health 85:136–145PubMedCrossRef

32.

Sorensen HT, Christensen S, Mehnert F et al (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case–control study. BMJ 336:813–816PubMedCrossRef

33.

Bunch TJ, Anderson JL, May HT et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824–828PubMedCrossRef

34.

Fisher A, Southcott E, Srikusalanukul W et al (2007) Relationships between myocardial injury, all-cause mortality, vitamin D, PTH and biochemical bone turnover markers in older patients with hip fractures. Ann Clin Lab Sci 37:222–232PubMed

35.

Steinbuch M, D’Agostino RB, Mandel JS et al (2002) Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 35:320–326PubMedCrossRef

36.

Black D, Delmas P, Eastell R, for the HORIZON Pivotal Fracture Trial et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

37.

Dobrucali A, Tobey NA, Awayda MS et al (2002) Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol 283:G576–G586PubMed

38.

Shao W, Orlando RC, Awayda MS, Shao W, Orlando RC, Awayda MS (2005) Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action. Am J Physiol Cell Physiol 289:C248–C256PubMedCrossRef

39.

Farhat G, Strotmeyer E, Newman A et al (2006) Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study. Calcif Tissue Int 79:102–111PubMedCrossRef

40.

Tuominen O, Ylitalo-Heikkala R, Vehmas T, Mucha I, Ylitalo P, Riutta A (2006) Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find Exp Clin Pharmacol 28:361–367PubMedCrossRef

41.

Delibasi T, Emral R, Erdogan MF, Kamel N (2007) Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther 24:319–325PubMedCrossRef

42.

Celiloglu M, Aydin Y, Balci P, Kolamaz T (2009) The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689–693PubMedCrossRef

43.

Nitta K, Akiba T, Suzuki K et al (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680–688PubMed

44.

Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215–222PubMedCrossRef

45.

Vestergaard P (2012) Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Calcif Tissue Int 90:22–29PubMedCrossRef

Title: Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
Authors: J.-H. Kang
J. J. Keller
H.-C. Lin
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2213-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database

Ten-year hip fracture incidence rate trends in a large California population, 1997–2006

Erratum to: Life-course evidence of birth weight effects on bone mass: systematic review and meta-analysis

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients

Pitfalls in the external validation of FRAX: response to Bolland et al.